Extended Data Table 2 Subgroup analysis of PFS2 in the ctDNA cohort patient population

From: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial

  1. Hazard ratios were determined by Cox Proportional Hazard Regression analysis and reported p-values are two-sided. CI: Confidence interval, CDK4/6i: CDK4/6 inhibitor, PFS2: progression free survival after two lines of treatment.
Back to article page